Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics Inc (NQ: TRDA )

19.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 19.04
Bid (Size) 7.620 (2)
Ask (Size) 27.70 (2)
Prev. Close 19.04
Today's Range 19.04 - 19.04
52wk Range 11.05 - 20.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
Via Benzinga
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+25.51%
+25.51%
1 Month
+9.61%
+9.61%
3 Month
+12.60%
+12.60%
6 Month
+17.97%
+17.97%
1 Year
+52.32%
+52.32%

More News

Read More
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Recap: Entrada Therapeutics Q4 Earnings
Via Benzinga
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces $100 Million Registered Direct Offering
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Entrada Therapeutics, Inc.
Via GlobeNewswire
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Entrada Therapeutics Reports First Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Insiders Buying America's Car-Mart And 2 Other Stocks
Via Benzinga
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Promotes Nathan J. Dowden to President
From Entrada Therapeutics, Inc.
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.